Clotting Disorders

Clotting Disorders

A collection of features and news articles published in ASH Clinical News related to clotting disorders.

Aspirin as Effective as Rivaroxaban for Preventing VTE After Total Hip or Knee Arthroplasty

Standard aspirin is as effective as the newer, direct oral anticoagulant (DOAC) rivaroxaban for preventing venous thromboembolism (VTE) in patients who have undergone total...

A Preview of ASH’s Venous Thromboembolism Clinical Practice Guidelines

In November 2015, the American Society of Hematology (ASH) and the McMaster University GRADE Center announced a collaboration to develop clinical practice guidelines on...

Is Oral Edoxaban an Alternative to Standard Anticoagulation in Cancer-Associated VTE?

Low-molecular-weight heparin is the standard, guideline-recommended anticoagulation therapy for patients with cancer and venous thromboembolism (VTE), but the daily subcutaneous injections can be burdensome....

Can Electronic Alerts Improve VTE Prophylaxis Delivery?

The use of thromboprophylaxis among hospitalized patients at risk for a venous thromboembolism (VTE) – a major complication of hospitalization – remains inconsistent. Both...

FDA Approves Lower Dose of Rivaroxaban for Recurrent VTE

The U.S. Food and Drug Administration approved 10 mg once-daily dosing for rivaroxaban to prevent recurrent venous thromboembolism (VTE) after at least six months...

Should IVC Filters Still Be Inserted into Thrombosis Management Guidelines?

Although the use of inferior vena cava (IVC) filters to prevent thrombosis has increased dramatically in the past decade, the risk-benefit ratio of these...

For Anticoagulation in Cancer-Associated Thrombosis, Is Less More?

Cancer-associated thrombosis is a major cause of morbidity and mortality in patients with cancer. While low-molecular-weight heparin (LMWH) anticoagulation therapy is a standard regimen...
Advertisement

Current Issue

March 2019, Volume 5, Issue 4

This issue features a look at the misconceptions about travel-associated blood clots, the treatment of young patients with myeloma, and more.